Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220657 | 0.91 | AQP1 (0.56) | AQP1SLC6A2SLC6A4SLC6A3PRKAB2 | |
| SCHEMBL4220701 | 0.88 | AQP1 (0.58) | AQP1SLC6A2SLC6A4SLC6A3PRKAB2 | |
| SCHEMBL4225490 | 0.88 | AQP1 (0.50) | AQP1SLC6A2SLC6A4SLC6A3PRKAB2 | |
| SCHEMBL4231148 | 0.87 | AQP1 (0.47) | AQP1SLC6A2SLC6A4SLC6A3PRKAB2 | |
| SCHEMBL4220125 | 0.85 | AQP1 (0.59) | AQP1SLC6A2SLC6A4SLC6A3PRKAB2 | |
| SCHEMBL4223655 | 0.82 | AQP1 (0.50) | AQP1SLC6A2SLC6A4SLC6A3PRKAB2 | |
| SCHEMBL4595097 | 0.82 | PARP1 (0.43) | AQP1 | |
| SCHEMBL4222416 | 0.81 | AQP1 (0.47) | AQP1SLC6A2SLC6A4SLC6A3PRKAB2 | |
| SCHEMBL4231247 | 0.81 | PRKAB2 (0.46) | SLC6A2SLC6A4SLC6A3PRKAB2PRKAG1 | |
| SCHEMBL4595096 | 0.81 | AQP1 (0.35) | AQP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | claimed |
| US-7396857-B2 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2008-07-08 | — | — | US | claimed |
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | claimed |
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | claimed |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20060258712-A1 | Methods for modulating bladder function | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258711-A1 | Treatment of drug abuse | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258713-A1 | Treatment of pain | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | GRIN3A, GRIN2A, BDNF | AQP1 3262/4885SLC6A2 36/4885SLC6A4 53/4885 |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | TTPA, GAP43, SLC6A3 | AQP1 1709/4885SLC6A2 88/4885SLC6A4 222/4885 |
| US-20060258711-A1 | Treatment of drug abuse | OPRK1, OPRM1, ADH1A | AQP1 1478/4885SLC6A2 14/4885SLC6A4 31/4885 |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | AQP1 1312/4885SLC6A2 4/4885SLC6A4 8/4885 |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | HTR1F, HTR2C, HTR3D | AQP1 3184/4885SLC6A2 43/4885SLC6A4 41/4885 |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885SLC6A2 62/4885SLC6A4 44/4885 |
| US-20060258713-A1 | Treatment of pain | OPRL1, OPRK1, OPRD1 | AQP1 694/4885SLC6A2 318/4885SLC6A4 581/4885 |
| US-20060258712-A1 | Methods for modulating bladder function | PDE3A, PDE3B, PDE2A | AQP1 137/4885SLC6A2 709/4885SLC6A4 1242/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885SLC6A2 62/4885SLC6A4 44/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | AQP1 2290/4885SLC6A2 99/4885SLC6A4 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.